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ABSTRACT
Background and aims We studied damage accrual
and factors determining development and progression of
damage in an international cohort of systemic lupus
erythematosus (SLE) patients.
Methods The Systemic Lupus International
Collaborating Clinics (SLICC) Inception Cohort recruited
patients within 15 months of developing four or more
1997 American College of Rheumatology (ACR) criteria
for SLE; the SLICC/ACR damage index (SDI) was measured
annually. We assessed relative rates of transition using
maximum likelihood estimation in a multistate model. The
Kaplan–Meier method estimated the probabilities for time
to ﬁrst increase in SDI score and Cox regression analysis
was used to assess mortality.
Results We recruited 1722 patients; mean (SD) age
35.0 (13.4) years at cohort entry. Patients with damage
at enrolment were more likely to have further worsening
of SDI (SDI 0 vs ≥1; p<0.001). Age, USA African race/
ethnicity, SLEDAI-2K score, steroid use and hypertension
were associated with transition from no damage to
damage, and increase(s) in pre-existing damage. Male
gender (relative transition rates (95% CI) 1.48 (1.06 to
2.08)) and USA Caucasian race/ethnicity (1.63 (1.08 to
2.47)) were associated with SDI 0 to ≥1 transitions;
Asian race/ethnicity patients had lower rates of new
damage (0.60 (0.39 to 0.93)). Antimalarial use was
associated with lower rates of increases in pre-existing
damage (0.63 (0.44 to 0.89)). Damage was associated
with future mortality (HR (95% CI) 1.46 (1.18 to 1.81)
per SDI point).
Conclusions Damage in SLE predicts future damage
accrual and mortality. We identiﬁed several potentially
modiﬁable risk factors for damage accrual; an integrated
strategy to address these may improve long-term
outcomes.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisys-
tem autoimmune disease in which adverse
long-term outcomes remain a major challenge. In
assessing patients with SLE, three disease dimen-
sions are considered in formal outcomes studies:
inﬂammatory disease activity, organ damage and
health related quality of life (HRQOL).1 Damage is
principally assessed using the Systemic Lupus
International Collaborating Clinics (SLICC)/
American College of Rheumatology (ACR) Damage
Index (SDI), which has been extensively vali-
dated.2 3 SDI items represent irreversible damage
that has occurred after the diagnosis of SLE.
However, an item does not have to be attributable
to lupus.2 As a general rule, items should be
present for at least 6 months and once recorded in
the SDI they are permanent such that the score
cannot decrease.
The mean SDI tends to increase over time,4 and
in time the majority of SLE patients will accrue
damage. The SDI also predicts future mortality.5–7
It is therefore important to understand factors
related to the development of damage. To date,
studies have mainly focused on established SLE
cohorts from a single centre or region.8–10 A
number of factors have been associated with higher
SDI scores, including older age at SLE onset,11 12
Hispanic and African ancestry race/ethnicity,8 13 14
chronic disease activity12 15 and major ﬂares.16
Steroid exposure also predicts future damage, espe-
cially late-onset damage.8 16 17 There is also accu-
mulating evidence that antimalarials (AMs) exert a
protective role even after adjusting for their pro-
pensity for use in milder disease.18
We aimed to study damage accrual over the early
years of follow-up in patients enrolled into the
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SLICC Inception Cohort. We focused on the rate of accrual of
total damage as well as the impact of demographic, racial/ethnic
and geographical variables. We also assessed the contribution of
disease-related factors, therapy, co-morbidities and serological
biomarkers to damage accrual. Finally, we sought to determine
the relationship between damage and HRQOL, as well as future
mortality.
METHODS
SLICC Inception Cohort study
SLICC comprises 31 centres from 11 countries in North
America, Latin America, Europe and Asia. An inception cohort
was recruited from 2000 to 2011. Data were submitted to the
co-ordinating centre at the University of Toronto at enrolment,
and patients were reviewed annually. Laboratory tests necessary
to evaluate disease activity and damage parameters were per-
formed locally. The study was approved by the Institutional
Research Ethics Boards of participating centres in accordance
with the Declaration of Helsinki’s guidelines for research in
humans.
Patients and clinical assessments
Patients were enrolled within 15 months of recognition of four
or more 1997 ACR classiﬁcation criteria for SLE.19 We
included patients who either had two study visits or had died
after their ﬁrst study visit, that is, patients who had two data
points to model statistically. There were no speciﬁc exclusion
criteria other than failing to meet four ACR criteria and it
being >15 months since diagnosis. We noted demographic fea-
tures including age, gender, race/ethnicity, geographical region
and years in post-secondary education. We also noted the
number of ACR criteria fulﬁlled by the baseline visit. At each
visit we also assessed the Systemic Lupus Erythematosus
Disease Activity Index 2000 (SLEDAI-2K)20 and the SDI.21 At
each visit we recorded whether the patient was taking corticos-
teroids (yes or no). In addition to steroid use, we also recorded
whether patients were taking AMs, immunosuppressives (ISs),
or both AMs and ISs. Co-morbidities (recorded at each visit)
included in our analysis were diabetes mellitus (physician con-
ﬁrmed diagnosis) and hypertension (systolic blood pressure
>140 mm Hg and/or diastolic blood pressure >90 mm Hg
and/or taking antihypertensive medications). Baseline sero-
logical markers included antibodies to double-stranded DNA
and C3 and C4 complement (in local clinical laboratories at
each centre). Antibodies to cardiolipin, β-2-glycoprotein I and
the lupus anti-coagulant were measured at a central laboratory
at the Oklahoma Medical Research Foundation as previously
described.22 HRQOL was assessed using the Medical
Outcomes Survey Short-Form 36 (SF-36). All patients provided
written informed consent.
Statistical analysis
Simple descriptive statistics were used to summarise enrolment
data. The SDI scores are discrete values that are observed over
time for each patient. Thus, we used a multistate model for
transitions among damage states, deﬁned by the SDI scores.
Speciﬁcally, at each visit a patient is assigned to one of the
damage states according to their current SDI score. Since
there are relatively few transitions to states 5–11, we merged
these states into one state indicating an SDI score ≥5. We
employed a multistate model with seven states, shown pictori-
ally below:
Patients may only show deterioration in the SDI damage
index over time and patients may die at any time during
observation.
Multistate models allow estimation of the transition rates
between these observed states, and these transition rates can be
modelled as a function of explanatory variables (both time-
independent and time-dependent). If λij(t) denotes the transition
intensity from state i to state j at time t, then λij(t) may be mod-
elled as follows:
lijðtÞ= l0ijðtÞ expðbTij XðtÞÞ
where λ0ij(t) denotes a baseline state i to state j transition inten-
sity at time t, T denotes matrix transpose, and X(t) is a vector of
explanatory variables with associated explanatory variable
effects on the state i to state j intensity denoted by βij.
In this work, we assume constant baseline transition intensities
for the relevant transitions. That is, λ0ij(t)=λ0ij for all t, for the
state i to state j transitions. Maximum likelihood estimation is
used to estimate the unknown model parameters (λ0ij and βij) for
each transition in the model together with their associated SEs.
The correlation among the states of a patient at the different
assessment visits is directly modelled through the Markov
assumption that the future evolution of a patient’s damage
process depends only on his/her current state and not on his/her
previous history. Initial modelling was based on a proportional
hazards assumption and assumed common explanatory variable
effects across selected transition rates. Notably we assumed that
transition rates and explanatory variable effects between damage
states where SDI ≥1 were the same and also that transitions to
death from these higher SDI states were equal. Explanatory vari-
able effects are reported as relative rates of transition, together
with corresponding 95% CIs, obtained using maximum likeli-
hood estimation. Age at diagnosis was standardised as (age in
years−34.5)/13.4. For disease activity we report effects corre-
sponding to 3-point increments in SLEDAI-2K.The Kaplan–
Meier method was used to estimate the probabilities relating to
time until ﬁrst worsening of SDI score.
For the modelling of HRQOL outcomes, we ﬁtted linear
models using generalised estimating equations (GEEs) to
account for the correlation among observations over time
within each patient. Standard Cox regression analysis was per-
formed with patient survival as the outcome and functions of
damage scores over time as explanatory variables.
RESULTS
There were a total of 1722 patients in the SLICC Inception
Cohort up to September 2011 and the mean (SD) number of
follow-up visits was 4.25 (2.72). Demographic and
disease-related factors at clinic entry are summarised in table 1.
At baseline, 671 patients had their SDI scores recorded as they
had more than 6 months of disease; of these 671 patients, 130
(19.4%) had an SDI score of 1 or more at the baseline visit. For
this group (ﬁgure 1A), the overall estimate of the probability of
SDI ﬁrst worsening at a time greater than 6 years since clinic
Clinical and epidemiological research
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entry is approximately 0.58 (ﬁgure 1A). Put another way, of the
348 patients who were observed 6 years after clinic entry, 178
(51.1%) had at least one item of damage by that time point.
When we stratiﬁed these 671 patients by baseline SDI score,
those with initial damage were signiﬁcantly more likely to have
further worsening of the SDI at each follow-up visit (p<0.001)
(ﬁgure 1B).
Transitions
There were 1502 (1337 female and 165 male) patients who had
at least two clinic visits or who had one clinic visit and subse-
quently died. In this group the predicted probability of remain-
ing with the same damage score over a 5-year period was
conditional on the pre-existing SDI score. The probability of
death also increased with higher SDI scores (table 2).
Inﬂuence of age, gender, race/ethnicity and
geographical region
Increasing age and male gender both had a signiﬁcant inﬂuence
on the probability of damage accrual. Higher standardised age
increased the risk of future damage, especially in those with no
current damage, and the inﬂuence of age was non-linear. The
signiﬁcant effect of (standardised age)2 suggests that the effect
of increases in age is most marked in older patients. Therefore,
assuming all other covariates have the same values for each age
at diagnosis compared to a patient aged 35.4 years (the mean
age of diagnosis), the relative transition rate was 1.58 for a
patient aged 50 years. Compared to a 50-year-old, the relative
transition rate was 2.51 for a 60-year-old, and for patients
between 60 and 70 years of age the transition rate increased by
a factor of 4.52. We also found that the effects of race/ethnicity
and location of study sites were not independent (Pearson’s
χ2=2096.775, 16 df; p<0.001) (data on ﬁle) and that both had
a signiﬁcant impact on damage accrual. We therefore combined
these into new variables (tables 3 and 4). Compared to
Caucasians in Europe or Canada, USA patients of African ances-
try had a higher risk of moving from no damage to damage and
also of progressing from baseline damage to higher damage
(relative transition rates (RTR) (95% CI) 1.99 (1.33 to 2.96)
and 2.55 (1.92, 3.40), respectively), while Asians had lower
transition rates (0.66 (0.43, 0.99)). Hispanic patients in Mexico
also had a higher risk of progressing from baseline damage to
higher damage (RTR (95% CI) 1.36 (1.02 to 1.83)) (tables 3
and 4).
Clinical, therapeutic and serological factors associated with
development and/or progression of damage
Corticosteroid use, immunosuppressive use, SLEDAI-2K score
and hypertension were all signiﬁcantly associated with both the
development of damage in patients free of damage at baseline,
as well as progression of damage in patients with baseline
damage (tables 3 and 4). The number of ACR criteria at enrol-
ment was also associated with higher transitions from SDI 0 to
≥1 (RTR (95% CI) 1.19 (1.06 to 1.34)) as was IS use (1.69
(1.08, 2.63)). In addition, AM use was associated with a
reduced transition rate to higher damage (0.60 (0.42, 0.84))
(tables 3 and 4).
Multivariate models
Multivariate, multistate models for both transitions conﬁrmed
that age, USA patients of African ancestry, SLEDAI-2K score,
steroid use and hypertension were predictive in both models of
damage accrual (tables 3 and 4). For transition from SDI 0 to
≥1, male gender (RTR (95% CI) 1.48 (1.06 to 2.08)) and USA
Caucasian race/ethnicity (RTR (95% CI) 1.63 (1.08 to 2.47))
were also associated with damage, while patients of Asian ethni-
city had lower rates of transition (RTR (95% CI) 0.60 (0.39 to
0.93)). For transitions from SDI ≥1 to higher damage, patients
taking AMs also had lower rates of transition (RTR (95% CI)
0.63 (0.44 to 0.89)). We found no evidence that baseline auto-
antibody status inﬂuenced damage accrual. We also noted a sig-
niﬁcant interaction between SLEDAI-2K and steroid use for
transitions from SDI 0 to ≥1 (SLEDAI/3×(Corticosteroids =
Yes); RTR (95% CI) 1.33 (1.02 to 1.74)). This suggests that the
association between disease activity and transition to damage is
greater for those patients taking corticosteroids.
In a secondary analysis we also assessed the inﬂuence of
having ‘active renal disease’ during follow-up. We found that
transition to higher damage states was greater in those with
Table 1 Baseline characteristics of the Systemic Lupus
International Collaborating Clinics cohort at entry to the study
Number of patients 1722
Age, years 35.0 (S.D. 13.4)
Gender
Female 1536 (89.2)
Male 186 (10.8)
Enrolment location
Canada 398 (23.1)
USA 497 (28.9)
Mexico 212 (12.3)
Europe 446 (25.9)
Asia 169 (9.8)
Race/ethnicity
Caucasian 830 (48.2)
Hispanic 268 (15.6)
Asian 271 (15.7)
African origin 280 (16.3)
Other 71 (4.1)
Disease phenotype at baseline
SLEDAI-2K 5.3 (5.3)*
Active renal disease 467 (27.1)
Thrombocytopenia (platelet count <100 000) 47 (2.7)
Medication use
Oral corticosteroids (CS) 1199 (69.6)
Average CS dose (mg/day) 24.1 (16.7)*
Highest CS dose (mg/day) 43.5 (74.3)*
Immunosuppressants 684 (39.7)
Antimalarials 1153 (67)
Co-morbidities
Systolic blood pressure (mm Hg) 119.5 (16.8)*
Diastolic blood pressure (mm Hg) 75.1 (11.1)*
Taking antihypertensives 505 (29.3)
Diabetes mellitus 60 (3.5)
Current smoker 263 (15.3)
Post-menopausal 162 (9.4)
Body mass index (kg/m2) 25.2 (5.9)*
Baseline serology
Anti-dsDNA positive 663 (38.5)
Low C3 and/or C4 complement 586 (34.0)
Anti-B2-GPI positive 241 (14)
Anti-cardiolipin positive 133 (7.7)
Lupus anticoagulant positive 208 (12.1)
*All data are n (%) of patients or mean (SD) where indicated.
SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.
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active renal disease (RTR (95% CI) SDI 0 to ≥1: 1.62 (1.10 to
2.38) and SDI ≥1 to higher damage: 1.66 (1.28 to 2.15),
respectively).
Inﬂuence of SDI on HRQOL
The physical component domains of the SF-36 were more inﬂu-
enced by damage than the mental health components (ﬁgure 2).
In a regression analysis with GEEs, the Physical Component
Summary score (PCS) declined steadily with increased damage
(table 5). We also found that PCS values were most inﬂuenced
by recent changes in damage (coefﬁcient (95% CI) −1.36
(−1.99 to −0.73) per SDI unit) and to a lesser extent by pre-
existing damage (coefﬁcient (95% CI) −0.39 (−0.36 to −0.58)).
Inﬂuence of SDI on mortality risk
To date there have been 41 deaths in the cohort. Using a Cox
proportional hazards model with SDI score classed as a numer-
ical variable rather than a factor, the SDI score was associated
with an increased HR of 1.46 (95% CI 1.18 to 1.81) for mor-
tality. A generalised likelihood ratio test of this model against a
model with SDI score stratiﬁed by factors produced a test
statistic of 14.25 (p=0.007 when compared to the quantiles of
a χ2 distribution on 4 df). This suggests that the level of damage
has a signiﬁcant effect on mortality but there is not a simple
relationship with SDI score (i.e. log-linear).
DISCUSSION
In a large international SLE inception cohort we have observed a
steady accrual of damage over time and as has been reported by
others, patients with damage are more likely to develop further
damage over time and are also at higher risk of future mortal-
ity.5 7 9 14 We also found that damage has a signiﬁcant effect on
physical functioning. This steady accrual of damage has also been
reported by other groups.10 14 23 24 We found no evidence of a
plateau effect in our early cohort; studies that have suggested a
plateau effect have tended to follow a cohort for more than
10 years.12 These observations are of clinical importance as the
SDI is relatively easy to administer with some training in routine
clinical settings and clearly identiﬁes lupus patients at particularly
increased risk of future adverse health outcomes.
Damage, especially a recent increase in the SDI, had a signiﬁ-
cant inﬂuence on physical functioning. Patients with recent
damage may experience the maximal physical disability soon
after acquiring the damage item. Over time, this may be amelio-
rated by physical adaptation or by corrective interventions. For
example, patients with cataracts may later have lens replace-
ment, patients with osteonecrosis may have joint arthroplasty,
and patients with stroke are likely to rehabilitate over time.
Our data also allowed us to estimate the probabilities of
developing future damage based on the patient’s current SDI
score. Such data allow us to consider how the SDI may be used
as a clinical trial endpoint. For example, the estimated probabil-
ity of remaining damage-free at 2 years is 0.844 if a patient has
no damage at baseline. If there is one unit of damage, the esti-
mated probability is 0.664 (similar for more than one). If we
want to detect a doubling of the odds of remaining damage-free
with an intervention, then in the ﬁrst case the sample size
needed (test at 5% and 80% power) would be approximately
Figure 1 (A) and (B) Kaplan–Meier plots demonstrating the estimate of the proportions of patients who remain free of damage progression/SDI
worsening for the patients within the SLICC cohort who had their SDI reported at their baseline visit (n=671) (A) and in this cohort stratiﬁed by
whether or not they had an SDI score 0 (n=541) or SDI >0 (n=130) at baseline (B). SDI, Systemic Lupus International Collaborating Clinics (SLICC)/
American College of Rheumatology (ACR) Damage Index.
Table 2 The predicted probability of a patients’ SDI state or
mortality in 5 years’ time, conditional on their current SDI score
Current
SDI state
Estimated probability of being in SDI state in 5 years’ time
0 1 2 3 4 ≥5 Death
0 0.655 0.198 0.086 0.030 0.006 0.002 0.022
1 0.360 0.341 0.192 0.055 0.026 0.027
2 0.323 0.375 0.155 0.107 0.040
3 0.354 0.264 0.310 0.072
4 0.204 0.705 0.092
≥5 0.880 0.120
SDI, Systemic Lupus International Collaborating Clinics (SLICC)/American College of
Rheumatology (ACR) Damage Index.
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670 (335 per group) and 349 (175 per group) in the second
scenario.
We found a non-linear effect of age, with the effect of
increases in age being most marked in older patients. Certain
damage items such as cataracts, stroke and osteoporosis are, of
course, more common with increasing age in the general popu-
lation. Therefore, there may be a greater sensitivity to the add-
itional effects of SLE and drug adverse effects with increasing
age due to reduced organ reserve. There were also important
differences among subsets of patients according to race/ethnicity
and location. USA patients of African ancestry have an increased
risk of damage accrual and USA Caucasians were also more
likely to develop new damage. Of note, Asians had a lower risk
of developing damage. There are a number of explanations for
these ﬁndings, including differences in the clinical phenotype
and/or its severity across different racial/ethnic groups. Response
to therapy may also vary in different racial/ethnic groups25 26
and socio-economic factors and access to healthcare may also
contribute. We used post-secondary education as a surrogate for
socio-economic status, which was not signiﬁcant in our models.
Other more direct measures of socio-economic status were not
collected but may have helped address this question more fully.
A number of similar factors drove development of new
damage and/or progression of existing damage. Levels of disease
activity, use of corticosteroids and hypertension all signiﬁcantly
inﬂuenced damage accrual. The signiﬁcant interaction between
disease activity and steroid therapy on new damage suggests that
both act together to enhance the development of irreversible
organ changes. Conversely, AMs were associated with reduced
progression of damage, particularly in patients with baseline
Table 3 Factors associated with the development of new damage that is, transition from SDI 0 to ≥1 in a multivariate, multistate model
Variable
Univariate model relative
transition rate (95% CI)
Multivariate model relative
transition rate (95% CI)
Gender: Female 1 1
Male 1.96 (1.42 to 2.71) 1.48 (1.06 to 2.08)
Standardised age at diagnosis (years) 1.21 (1.09 to 1.34) 1.30 (1.12 to 1.52)
(Standardised age at diagnosis (years))2 1.14 (1.08 to 1.20) 1.12 (1.03 to 1.23)
Ethnicity/location
Caucasian (Canada/Europe) 1 1
Caucasian (USA) 1.47 (0.98 to 2.20) 1.63 (1.08 to 2.47)
Hispanic (Mexico) 1.44 (0.98 to 2.12) 1.17 (0.75 to 1.82)
Hispanic (elsewhere) 1.74 (0.88 to 3.44) 1.71 (0.85 to 3.43)
African (USA) 1.99 (1.33 to 2.96) 1.58 (1.03 to 2.44)
African (elsewhere) 1.47 (0.95 to 2.27) 1.30 (0.83 to 2.03)
Asian 0.66 (0.43 to 0.99) 0.60 (0.39 to 0.93)
Other 1.76 (0.98 to 3.14) 1.51 (0.83 to 2.73)
Post-secondary education*: No 1 1
Yes 0.76 (0.59 to 0.97) 0.80 (0.61 to 1.04)
No. of ACR criteria fulfilled at enrolment 1.19 (1.06 to 1.34) 1.12 (0.99 to 1.27)
(SLEDAI-2K)/3 1.25 (1.15 to 1.35) 1.17 (1.07 to 1.27)
Corticosteroid use: No 1 1
Yes 1.81 (1.40 to 2.34) 1.64 (1.21 to 2.21)
Additional SLE therapy (with or without corticosteroids)
Antimalarials (AMs) only: No 1 1
Yes 0.86 (0.57 to 1.29) 0.81 (0.53 to 1.22)
Immunosuppressants (ISs) only: No 1 1
Yes 1.69 (1.08 2.63) 1.13 (0.71 to 1.80)
AMs and ISs: No 1 1
Yes 1.28 (0.85 to 1.92) 1.06 (0.69 to 1.62)
Diabetes: No NA NA
Yes NA NA
Hypertension: No 1 1
Yes 2.61 (1.97 to 3.46) 1.71 (1.27 to 2.31)
Anti-ds-DNA at baseline: No 1
Yes 0.98 (0.76 to 1.28)
Hypocomplementaemia at baseline: No 1
Yes 1.08 (0.83 to 1.39)
Anti-B2-GPI at baseline: No 1
Yes 0.86 (0.58 to 1.28)
Anticardiolipin at baseline: No 1
Yes 0.90 (0.61 to 1.35)
Lupus anticoagulant at baseline: No 1
Yes 1.24 (0.90 to 1.70)
*A ‘missing’ indicator was included for the 6.1% of patients for whom this information was lacking.
SDI, Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus
Erythematosus Disease Activity Index 2000.
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damage. These are all potentially modiﬁable risk factors. A
multidimensional approach to damage prevention may therefore
be needed and components of this would include better sup-
pression of disease activity, minimising/avoiding corticosteroid
use, use of AMs from an early stage and close control of hyper-
tension. Also, if a novel therapy for SLE could achieve better
disease control and steroid-sparing/avoidance, this ‘double
beneﬁt’ may translate to signiﬁcant effects on damage accrual;
indeed the interaction of inﬂammation and steroid therapy we
found suggests there may be major gains in reducing future
damage by such an approach.
Our study has a number of strengths. This is a large inter-
national inception cohort from diverse racial/ethnic backgrounds
and geographical locations which has helped us understand how
these factors inﬂuence damage development. We could also esti-
mate probabilities of damage progression to help inform the use
of the SDI as a clinical trial endpoint.
There are some limitations to our study. Patients were
followed annually so it is difﬁcult to fully model disease activity
and therapeutic exposures. We also lack data on psychosocial
factors which may inﬂuence damage progression.
Sundaramurthy et al previously demonstrated that locus of
control and time orientation were strong predictors of future
damage.27 Our cohort, followed at a number of major teaching
centres, may represent a lower estimate of damage accrual rates
than that seen in general rheumatology practice; conversely, the
tertiary referral case mix in many centres may act in the oppos-
ite way to inﬂuence our estimates. Finally, while our multivariate
Table 4 Factors associated with progression of damage in patients with present damage that is, transition from SDI ≥1 to a higher score in a
multivariate, multistate model
Variable
Univariate model relative
transition rate (95% CI)
Multivariate model relative
transition rate (95% CI)
Gender: Female 1 1
Male 1.19 (0.93 to 1.52) 1.12 (0.86 to 1.46)
Standardised age at diagnosis (years) 0.93 (0.86 to 1.81) 1.00 (0.87 to 1.14)
(Standardised age at diagnosis (years))2 1.06 (1.02 to 1.09) 1.07 (1.00 to 1.14)
Ethnicity/location
Caucasian (Canada/Europe) 1 1
Caucasian (USA) 1.25 (0.90 to 1.74) 1.26 (0.89 to 1.78)
Hispanic (Mexico) 1.36 (1.02 to 1.83) 1.08 (0.76 to 1.54)
Hispanic (elsewhere) 0.37 (0.09 to 1.52) 0.37 (0.09 to 1.52)
African (USA) 2.55 (1.92 to 3.40) 2.39 (1.75 to 3.27)
African (elsewhere) 1.07 (0.72 to 1.57) 0.99 (0.65 to 1.50)
Asian 1.10 (0.77 to 1.57) 0.95 (0.65 to 1.38)
Other 1.08 (0.58 to 2.01) 1.00 (0.53 to 1.89)
Post-secondary education*: No 1 1
Yes 0.98 (0.80 to 1.19) 1.00 (0.81 to 1.24)
No. of ACR criteria fulfilled at enrolment 1.04 (0.95 to 1.13) 1.01 (0.92 to 1.11)
(SLEDAI-2k)/3 1.11 (1.05 to 1.17) 1.10 (1.03 to 1.16)
Corticosteroid use: No 1 1
Yes 1.69 (1.35 to 2.11) 1.43 (1.12 to 1.84)
Additional SLE therapy (with or without corticosteroids)
Antimalarials (AMs) only: No 1 1
Yes 0.60 (0.42 to 0.84) 0.63 (0.44 to 0.89)
Immunosuppressants (ISs) only: No 1 1
Yes 1.05 (0.76 to 1.45) 0.94 (0.66 to 1.33)
AMs and ISs: No 1 1
Yes 0.95 (0.69 to 1.29) 0.83 (0.60 to 1.16)
Diabetes: No 1 1
Yes 1.59 (0.93 to 2.73) 0.96 (0.54 to 1.70)
Hypertension: No 1 1
Yes 1.97 (1.59 to 2.45) 1.61 (1.28 to 2.03)
Anti-ds-DNA at baseline: No 1
Yes 0.97 (0.77 to 1.21)
Hypocomplementaemia at baseline: No 1
Yes 1.14 (0.92 to 1.41)
Anti-B2-GPI at baseline: No 1
Yes 1.14 (0.82 to 1.61)
Anticardiolipin at baseline: No 1
Yes 1.35 (0.98 to 1.86)
Lupus anticoagulant at baseline: No 1
Yes 1.14 (0.87 to 1.48)
*A ‘missing’ indicator was included for the 6.1% of patients for whom this information was lacking.
ACR, American College of Rheumatology; SLE, systemic lupus erythematosus; SLEDAI-2k, Systemic Lupus Erythematosus Disease Activity Index 2000.
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modelling suggests an independent effect of steroids and AMs
on certain outcomes, we cannot exclude the possibility of
residual confounding and that unmeasured factors may also
inﬂuence the use of these agents in SLE patients.
In conclusion, we describe a steady increase in damage over
time in SLE patients, with pre-existing damage being an import-
ant predictor of future damage accrual. We have also identiﬁed
a number of modiﬁable risk factors that can be targeted as an
integrated strategy. Overall, the SDI may therefore act in a way
analogous to an erosion score in rheumatoid arthritis and could
also act as a valid intermediate surrogate outcome for future
mortality in SLE clinical trials.
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